Giraudo Bryan's Form 4 filing
Protagonist Therapeutics, Inc (PTGX) · filed May 11, 2026
- Accession no.
- 0001104659-26-058860
- Filed
- May 11, 2026
- Trade date
- May 7-8, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $5.92M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Giraudo BryanCIK 0001740847 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | Common Stock | MOption exerciseAcquired | +24,000 | $6.45 | +$154,800 | 31,825 | Direct | |
| May 7, 2026 | Common Stock | MOption exerciseAcquired | +12,000 | $6.98 | +$83,760 | 43,825 | Direct | |
| May 7, 2026 | Common Stock | SSaleDisposed | −36,000 | $100.14F2 | −$3,605,040 | 27,825 | Direct | |
| May 7, 2026 | Common Stock | SSaleDisposed | −12,000 | $100.07 | −$1,200,840 | 6,000 | Indirect | |
| May 8, 2026 | Common Stock | SSaleDisposed | −6,000 | $100.00 | −$600,000 | 0 | Indirect | |
| May 8, 2026 | Common Stock | SSaleDisposed | −5,130 | $100.00 | −$513,000 | 12,695 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | Common Stock | MOption exerciseDisposed | −24,000 | $0.00 | $0 | 0 | Direct | |
| May 7, 2026 | Common Stock | MOption exerciseDisposed | −12,000 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $98.69 to $104.67. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.